2-(1H-indol-2-yl)-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 2-(1H-indol-2-yl)-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
• 化学式: C₁₉H₁₅N₃O
• 分子量: 301.3
• InChiKey: QLSLBMSGCHNZKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  1

文献信息

• Substituted indoles which are parp inhibitors
  申请人：——

  公开号：US20040067949A1

  公开（公告）日：2004-04-08

  The present invention relates to novel indole derivatives, to their preparation and to their use, as inhibitors of the enzyme poly(ADP-ribose)polymerase or PARP (EC 2.4.2.30), for producing drugs.

  本发明涉及新型吲哚衍生物、它们的制备及其作为聚（ADP-核糖）聚合酶或 PARP（EC 2.4.2.30）的抑制剂用于生产药物的用途。
• Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye
  申请人：Zhang Jinzhong

  公开号：US20080305994A1

  公开（公告）日：2008-12-11

  A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an opthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase (“PARP”). The composition can also include a modulator of pro-inflammatory gene expression.
• US7087637B2
  申请人：——

  公开号：US7087637B2

  公开（公告）日：2006-08-08
• [EN] PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉ PERMETTANT DE TRAITER, RÉDUIRE, AMÉLIORER, ATTÉNUER, OU PRÉVENIR LA SÉCHERESSE OCULAIRE
  申请人：BAUSCH & LOMB

  公开号：WO2008154129A1

  公开（公告）日：2008-12-18

  [EN] A composition for treating, reducing, ameliorating, alleviating, or preventing a dry eye condition or an ophthalmologic disorder that has an etiology in inflammation comprises an inhibitor of activity of poly(ADP-ribose) polymerase ("PARP"). The composition can also include a modulator of pro-inflammatory gene expression.
  [FR] La présente invention concerne une composition permettant de traiter, réduire, améliorer, atténuer, ou prévenir un état de sécheresse oculaire ou un trouble ophtalmologique d'origine inflammatoire qui comprend un inhibiteur de l'activité de poly(ADP-ribose)-polymérase ('PARP'). La composition peut également inclure un modulateur de l'expression de gène pro-inflammatoire.